Traders should monitor the April 11 and April 15 presentations for any new efficacy or safety data from the SOL-1 trial, which could influence sentiment around AXPAXLI™'s regulatory and commercial potential. Absent data or approval, this filing is routine scientific communication.
Price Chart
Executive Summary
Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy AXPAXLI™ (OTX-TKI) in wet AMD at major ophthalmology conferences in April 2026. The data disclosures are part of ongoing scientific dissemination, not a regulatory approval or clinical trial result announcement.
Key Facts
- Ocular Therapeutix will present SOL-1 Phase 3 data for AXPAXLI™ (OTX-TKI) in wet AMD at the Vit-Buckle Society meeting on April 11, 2026.
- Additional presentations on diabetic retinal disease and wet AMD will occur at CNO 2026 in Buenos Aires from April 15–17, 2026.
- AXPAXLI™ is an axitinib intravitreal hydrogel in Phase 3 trials for wet AMD and diabetic retinal disease, including NPDR.
- No new clinical data, FDA decision, or commercial update was released—this is a schedule of upcoming scientific presentations.
Financial Impact
Minimal near-term financial impact; no revenue or cost implications disclosed
Risk Factors
- Data presented at the conferences could reveal safety concerns or lower-than-expected efficacy for AXPAXLI™
- Failure to show superiority over existing anti-VEGF therapies could limit commercial adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266467 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access